Skip to content

Bortezomib combined with chemotherapy in adults with relapsed/refractory acute lymphoblastic leukemia

Bortezomib combined with chemotherapy in adults with relapsed/refractory acute lymphoblastic leukemia

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049664
Enrollment
Unknown
Registered
2021-08-08
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Acute Lymphoblastic Leukemia

Interventions

Sponsors

Jiaozuo People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for relapsed/refractory ALL in the ''Guidelines for the Diagnosis and Treatment of Adult Acute Lymphoblastic Leukemia in China (2016 Edition)''; 2. Aged 18 to 70 years old; 3. No serious organ dysfunction; 4. No history of allergy to the drugs in this group; 5. Each subject (or his legal representative) must sign an informed consent form, indicating that he/she understands the purpose and procedures of the study and is willing to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patients with a second tumor; 2. Patients with severe neurological diseases; 3. Uncontrolled or serious infection; 4. The patient or family members request to withdraw from the trial.

Design outcomes

Primary

MeasureTime frame
complete remission rate;minimal residual disease;overall survival rate;event-free survival;

Countries

China

Contacts

Public ContactSong Qinglin

Jiaozuo People's Hospital

hnjzsql@163.com+86 1334391865

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026